Skip to main content

Choroidal Neovascularization - Pipeline Review, H2 2018 - ResearchAndMarkets.com

The "Choroidal Neovascularization - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Choroidal Neovascularization - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Choroidal Neovascularization - Overview
  4. Choroidal Neovascularization - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Choroidal Neovascularization - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Choroidal Neovascularization - Companies Involved in Therapeutics Development
  • 3SBio Inc
  • F. Hoffmann-La Roche Ltd
  • Formycon AG
  • Iconic Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Lupin Ltd
  • Mabion SA
  • NovelMed Therapeutics Inc
  • Noxxon Pharma AG
  • Promedior Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zzqpxk/choroidal?w=4

Contacts:

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Optical Disorders Drugs

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.